Disease · MONDO_0004964

peripheral T-cell lymphoma, not otherwise specified

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. peripheral T-cell lymphoma, not otherwise specified. Diseases, record MONDO_0004964. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004964

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: peripheral T-cell lymphoma, not otherwise specified; Open Targets
Open Targets ID: MONDO_0004964; Open Targets
Other names: unspecified peripheral T-cell lymphoma; Open Targets
NCI Thesaurus: C4340; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 68 drugs, from DailyMed; Open Targets

Drugs68

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PRALATREXATE	CHEMBL1201746	Small molecule	Approval	DailyMed	7	6	6	Drugs and targets
BELINOSTAT	CHEMBL408513	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
ROMIDEPSIN	CHEMBL343448	Protein	Approval	DailyMed	5	4	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	25	25	25	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	11	11	10	Drugs and targets
TUCIDINOSTAT	CHEMBL3621988	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 68

See all 68 drugs

Targets112

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	5	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 112

See all 112 targets

Trials76

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03372057	A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	Phase 2	156	2025-02-28	Peripheral T-cell Lymphoma	DUVELISIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02264613	ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas	Phase 1/2	142	2026-01-13	Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma	PALBOCICLIB, SULANEMADLIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00426764	A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma	Phase 2	131	2012-08-13	Peripheral T-cell Lymphoma	ROMIDEPSIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00865969	Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma	Phase 2	129	2021-09-16	Peripheral T-cell Lymphoma	BELINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT00481871	Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies	Phase 1/2	119	2012-09-18	Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia	GEMCITABINE HYDROCHLORIDE, PRALATREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00364923	Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma	Phase 2	115	2010-02-01	Peripheral T-cell Lymphoma	PRALATREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02362997	Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL	Phase 2	82	2022-12-08	Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma	PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2	77	2022-05-04	Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma	TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02653976	A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	Phase 2	67	2024-01-26	Peripheral T-Cell Lymphoma	DARINAPARSIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00274651	A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas	Phase 2	53	2014-10-27	Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma	BELINOSTAT	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 76

See all 76 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A (CTCL, ITT Population) vs Arm B (PTCL, ITT Population): serious adverse events	7 of 29	8 of 24	53	NCT00274651	Trial comparisons
Dose Regimen A (DR-A) PTCL Expansion vs Dose Regimen C (DR-C) PTCL Expansion: Determine Overall Response Rate	2 of 21	2 of 16	37	NCT02264613	Trial comparisons
Pralatrexate Arm vs Observation Arm: deaths from any cause	3 of 14	1 of 7	21	NCT01420679	Trial comparisons
Pralatrexate Arm vs Observation Arm: serious adverse events	4 of 14	0 of 7	21	NCT01420679	Trial comparisons
Classic Hodgkin Lymphoma vs PTCL: deaths from any cause	0 of 6	2 of 6	12	NCT03947255	Trial comparisons
Classic Hodgkin Lymphoma vs PTCL: serious adverse events	0 of 5	2 of 6	11	NCT03947255	Trial comparisons

Papers from its trials44

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31123029	RESULT	1	PubMed
30694529	RESULT	1	PubMed
30301414	RESULT	1	PubMed
29072976	RESULT	1	PubMed
28516671	RESULT	1	PubMed
26921086	RESULT	1	PubMed
25605745	RESULT	1	PubMed
25482745	RESULT	1	PubMed
25113753	RESULT	1	PubMed
22271479	RESULT	1	PubMed

1 to 10 of 44

See all 44 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004964

GET https://conductscience.org/api/diseases/v1/MONDO_0004964/drugs?page=2

API reference For AI assistants